WESTMINSTER, CA / ACCESSWIRE / October 4, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced the publication of an important peer-reviewed article confirming that its innovative water treatment technology, the Advanced Oxidation System (AOS), generates highly energetic iodine molecules. The article establishes the foundational scientific principles about why the AOS is a powerful, efficient, and novel water treatment technology.
The BioLargo AOS, which is currently deployed in a demonstration pilot project at a municipal wastewater treatment plant, is a ground-breaking water treatment platform that provides rapid and effective disinfection and concurrent organics removal while consuming less electricity than other common treatment technologies. The AOS has previously been shown in bench-scale and pilot-scale studies to exhibit greater water disinfection and decontamination performance than would be expected in similar water treatment technologies. This spurred BioLargo scientists and academic collaborators to elucidate the exact electrochemical mechanisms of the AOS in this study.
The paper, published in the American Chemical Society's journal ES&T Water, examines the mechanism by which the BioLargo AOS produces such rapid and effective disinfection performance relative to past electrochemical water treatment technologies. The study used the Canadian Light Source particle accelerator to perform advanced measurements of the chemical reactions that occur inside the AOS during operation. This technique revealed that the AOS generates highly oxidized iodine molecules that the researchers concluded are likely responsible for the technology's elevated disinfection efficacy. These special iodine molecules were only present inside the active layers of the AOS and were neutralized before water flowed out of the AOS.
Dr. Richard Smith, President of BioLargo Water commented, "Our AOS technology is a technical leap forward in advanced water treatment. This study is integral in showing why the technology produces such high performance while consuming so little energy."
Access the journal article in ACS EST&T Water here: https://pubs.acs.org/doi/full/10.1021/acsestwater.1c00149
Or read the free, open-source version published on ChemRxiv.org, here: https://chemrxiv.org/engage/chemrxiv/article-details/6102c081537d10350580560a
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.